aTYR PHARMA (ATYR) Amortization of Deferred Charges (2021 - 2026)
aTYR PHARMA's (ATYR) quarterly Amortization of Deferred Charges came in at $232000.0 in Q1 2026, up 7.41% YoY from $216000.0 in Q1 2025, and up 1.75% on a QoQ basis from $228000.0 in Q4 2025.
aTYR PHARMA (ATYR) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 6 years of Amortization of Deferred Charges data on file, last reported at $232000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 7.41% year-over-year to $232000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $905000.0 (up 98.46% YoY) and the FY2025 annual result came in at $889000.0, up 6.85% from the prior year.
- Amortization of Deferred Charges climbed to $232000.0 in Q1 2026, from $228000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $817000.0 in Q3 2023 to a low of -$176000.0 in Q4 2024.
- A 5-year average of $327352.9 and a median of $228000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2024 — Amortization of Deferred Charges sank 175.86% — and 2025, when it jumped 229.55%.
- Tracing ATYR's Amortization of Deferred Charges over 5 years: stood at $658000.0 in 2022, then plunged by 64.74% to $232000.0 in 2023, then slumped by 175.86% to -$176000.0 in 2024, then jumped by 229.55% to $228000.0 in 2025, then advanced by 1.75% to $232000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $232000.0 (Q1 2026), $228000.0 (Q4 2025), and $224000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 237,000.00 |
| Jun 30, 2026 | 237,000.00 |
| Mar 31, 2026 | 232,000.00 |
| Mar 31, 2026 | 232,000.00 |
| Dec 31, 2025 | 228,000.00 |
| Dec 31, 2025 | 228,000.00 |
| Sep 30, 2025 | 224,000.00 |
| Sep 30, 2025 | 224,000.00 |
| Jun 30, 2025 | 221,000.00 |
| Jun 30, 2025 | 221,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Sep 30, 2024 | 210,000.00 |
| Sep 30, 2024 | 210,000.00 |
| Jun 30, 2024 | 206,000.00 |
| Jun 30, 2024 | 206,000.00 |
| Mar 31, 2024 | 592,000.00 |
| Mar 31, 2024 | 592,000.00 |